Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. more
Time Frame | RGNX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -13.22% | -3.39% | 0.2% |
1-Month Return | -16.55% | -1.92% | 2.72% |
3-Month Return | -34.59% | -10.54% | 7.31% |
6-Month Return | -27.23% | -4.47% | 10.44% |
1-Year Return | -56.59% | 4.06% | 27.53% |
3-Year Return | -73.97% | 0.94% | 30.88% |
5-Year Return | -80.3% | 36.67% | 89.21% |
10-Year Return | -72.18% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 35.23M | 154.57M | 470.35M | 112.72M | 90.24M | [{"date":"2019-12-31","value":7.49,"profit":true},{"date":"2020-12-31","value":32.86,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":23.97,"profit":true},{"date":"2023-12-31","value":19.19,"profit":true}] |
Cost of Revenue | 8.24M | 35.71M | 51.83M | 54.55M | 37.21M | [{"date":"2019-12-31","value":15.11,"profit":true},{"date":"2020-12-31","value":65.48,"profit":true},{"date":"2021-12-31","value":95.03,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":68.22,"profit":true}] |
Gross Profit | 26.99M | 118.85M | 418.51M | 58.18M | 53.03M | [{"date":"2019-12-31","value":6.45,"profit":true},{"date":"2020-12-31","value":28.4,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":13.9,"profit":true},{"date":"2023-12-31","value":12.67,"profit":true}] |
Gross Margin | 76.61% | 76.89% | 88.98% | 51.61% | 58.76% | [{"date":"2019-12-31","value":86.1,"profit":true},{"date":"2020-12-31","value":86.42,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":58,"profit":true},{"date":"2023-12-31","value":66.04,"profit":true}] |
Operating Expenses | 175.99M | 238.09M | 258.53M | 321.06M | 321.16M | [{"date":"2019-12-31","value":54.8,"profit":true},{"date":"2020-12-31","value":74.13,"profit":true},{"date":"2021-12-31","value":80.5,"profit":true},{"date":"2022-12-31","value":99.97,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (149.00M) | (119.23M) | 159.98M | (262.88M) | (268.13M) | [{"date":"2019-12-31","value":-93.14,"profit":false},{"date":"2020-12-31","value":-74.53,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-164.32,"profit":false},{"date":"2023-12-31","value":-167.6,"profit":false}] |
Total Non-Operating Income/Expense | 54.46M | 16.72M | (44.29M) | (40.44M) | (5.08M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":30.71,"profit":true},{"date":"2021-12-31","value":-81.33,"profit":false},{"date":"2022-12-31","value":-74.26,"profit":false},{"date":"2023-12-31","value":-9.34,"profit":false}] |
Pre-Tax Income | (97.49M) | (106.01M) | 141.25M | (280.40M) | (263.65M) | [{"date":"2019-12-31","value":-69.02,"profit":false},{"date":"2020-12-31","value":-75.05,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-198.52,"profit":false},{"date":"2023-12-31","value":-186.66,"profit":false}] |
Income Taxes | (2.75M) | 5.24M | 13.41M | (84.00K) | (152.00K) | [{"date":"2019-12-31","value":-20.55,"profit":false},{"date":"2020-12-31","value":39.08,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-0.63,"profit":false},{"date":"2023-12-31","value":-1.13,"profit":false}] |
Income After Taxes | (94.73M) | (111.25M) | 127.84M | (280.32M) | (263.49M) | [{"date":"2019-12-31","value":-74.1,"profit":false},{"date":"2020-12-31","value":-87.02,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-219.27,"profit":false},{"date":"2023-12-31","value":-206.11,"profit":false}] |
Income From Continuous Operations | (94.73M) | (111.25M) | 127.84M | (280.32M) | (260.54M) | [{"date":"2019-12-31","value":-74.1,"profit":false},{"date":"2020-12-31","value":-87.02,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-219.27,"profit":false},{"date":"2023-12-31","value":-203.8,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (94.73M) | (111.25M) | 127.84M | (280.32M) | (263.49M) | [{"date":"2019-12-31","value":-74.1,"profit":false},{"date":"2020-12-31","value":-87.02,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-219.27,"profit":false},{"date":"2023-12-31","value":-206.11,"profit":false}] |
EPS (Diluted) | (2.59) | (2.80) | 2.74 | (6.50) | (6.03) | [{"date":"2019-12-31","value":-94.53,"profit":false},{"date":"2020-12-31","value":-102.19,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-237.23,"profit":false},{"date":"2023-12-31","value":-220.07,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
RGNX | |
---|---|
Cash Ratio | 2.49 |
Current Ratio | 3.05 |
Quick Ratio | 3.17 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
RGNX | |
---|---|
ROA (LTM) | -26.03% |
ROE (LTM) | -71.87% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
RGNX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.42 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.58 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
RGNX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 4.98 |
P/B | 1.39 |
Price/FCF | NM |
EV/R | 2.94 |
EV/Ebitda | NM |
PEG | 0.26 |
Regenxbio Inc (RGNX) share price today is $8.411
Yes, Indians can buy shares of Regenxbio Inc (RGNX) on Vested. To buy Regenxbio Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RGNX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Regenxbio Inc (RGNX) via the Vested app. You can start investing in Regenxbio Inc (RGNX) with a minimum investment of $1.
You can invest in shares of Regenxbio Inc (RGNX) via Vested in three simple steps:
The 52-week high price of Regenxbio Inc (RGNX) is $28.8. The 52-week low price of Regenxbio Inc (RGNX) is $8.06.
The price-to-earnings (P/E) ratio of Regenxbio Inc (RGNX) is
The price-to-book (P/B) ratio of Regenxbio Inc (RGNX) is 1.39
The dividend yield of Regenxbio Inc (RGNX) is 0.00%
The market capitalization of Regenxbio Inc (RGNX) is $419.65M
The stock symbol (or ticker) of Regenxbio Inc is RGNX